ProMIS Neurosciences IncNASDAQ:PMN
- LAST PRICE1.9800
- TODAY'S CHANGE (%)0.0300 (1.5385%)
- Bid / Lots0.9500/ 1
- Ask / Lots2.0200/ 1
- Open / Previous Close1.9600 / 1.9500
- Day Range
- 52 Week Range
- Volume1,032
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PMN |
|---|---|---|
| 11:08 ET | 600 | 1.96 |
| 03:27 ET | 100 | 1.98 |
Apr 9, 2024
Apr 4, 2024
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April, from 7:00AM ET on Thursday Apr 04, 2024 by Dow Jones
7:00AM ET on Thursday Apr 04, 2024 by Dow Jones
Apr 1, 2024
*DJ ProMIS Neurosciences 2023 Loss/Shr $1.07 >PMN, from 4:24PM ET on Monday Apr 01, 2024 by Dow Jones
4:24PM ET on Monday Apr 01, 2024 by Dow JonesProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights, from 4:15PM ET on Monday Apr 01, 2024 by Dow Jones
4:15PM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ProMIS Neurosciences Inc | 37.5M | -1.6x | --- |
Xilio Therapeutics Inc | 37.6M | -0.4x | --- |
NextCure Inc | 37.7M | -0.6x | --- |
Estrella Immunopharma Inc | 37.3M | -0.5x | --- |
Zyversa Therapeutics Inc | 37.9M | 0.0x | --- |
NRX Pharmaceuticals Inc | 37.1M | -1.2x | --- |
Company Information
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
Contact Information
- Headquarters
- Suite 200, 1920 Yonge StreetTORONTO, ON, Canada M4S 3E2
- Phone
- 416-847-6898
- Fax
- ---
Executives
- Executive Chairman of the Board
- Eugene Williams
- Chief Executive Officer, Director
- Gail Farfel
- Co-Founder, Chief Scientific Officer, Director
- Neil Cashman
- Chief Financial Officer
- Daniel Geffken
- Chief Operating Officer
- Gavin Malenfant
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $37.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 19.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.69 |
EPS | $-1.22 |
Book Value | $0.20 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
